{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:59:24Z","timestamp":1780894764106,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004206","name":"The University of Osaka","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We investigated the long-term visual and structural outcomes in eyes with myopic macular neovascularization (MNV) treated with anti-vascular endothelial growth factor (VEGF) therapy and focused on developmental patterns and associated factors of MNV-related atrophy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, observational study included 39 eyes with treatment-na\u00efve myopic MNV who received intravitreal ranibizumab or aflibercept and were followed for at least 5 years. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), and central choroidal thickness (CCT) were measured longitudinally. Color fundus photography classified the atrophy as perilesional and foveal. Factors associated with atrophy and final BCVA were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over 5 years, the mean BCVA significantly improved from baseline and remained significantly better at all time points (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05); the CRT and CCT decreased significantly from baseline (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). MNV-related atrophy developed in 59% of eyes and foveal atrophy in 38%. Three atrophic types were identified: perilesional (74%), patchy atrophy expansion (22%), and atrophy following subretinal hemorrhage (4%). Perilesional atrophy developed in older patients. Eyes with perilesional or foveal atrophy had worse baseline BCVA, thicker baseline CRT, larger greatest linear dimension, more frequent Meta-Analysis for Pathologic Myopia category 3, subfoveal MNV, and more injections than without atrophy, although none remained significant in multivariate analysis. Multivariate analysis showed foveal atrophy to be the strongest determinant of poorer BCVA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti-VEGF therapy was associated with favorable long-term visual outcomes in myopic MNV. However, MNV-related atrophy, particularly foveal atrophy, was associated with visual decline. The presence of multiple atrophic patterns may suggest heterogeneous underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07299-w","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:33:16Z","timestamp":1780893196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Five-year real-world outcomes and patterns of MNV-related atrophy after anti-VEGF therapy in eyes with pathologic myopia"],"prefix":"10.1007","author":[{"given":"Kaori","family":"Sayanagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Shunto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"7299_CR1","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","volume":"124","author":"CMG Cheung","year":"2017","unstructured":"Cheung CMG, Arnold JJ, Holz FG et al (2017) Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 124:1690\u20131711. https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.028","journal-title":"Ophthalmology"},{"key":"7299_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00417-023-06271-2","volume":"262","author":"L Glachs","year":"2024","unstructured":"Glachs L, Embacher S, Berghold A et al (2024) Treatment of myopic choroidal neovascularization: a network meta-analysis and review. Graefes Arch Clin Exp Ophthalmol 262:1693\u20131722. https:\/\/doi.org\/10.1007\/s00417-023-06271-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7299_CR3","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1097\/IAE.0000000000003869","volume":"43","author":"R Sakata","year":"2023","unstructured":"Sakata R, Miyata M, Ooto S et al (2023) Ten-year visual outcome and change in chorioretinal atrophy after intravitreal ranibizumab for macular neovascularization in pathologic myopia. Retina 43:1863\u20131871. https:\/\/doi.org\/10.1097\/IAE.0000000000003869","journal-title":"Retina"},{"key":"7299_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1097\/IAE.0000000000001313","volume":"37","author":"K Kasahara","year":"2017","unstructured":"Kasahara K, Moriyama M, Morohoshi K et al (2017) Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia. Retina 37:1055\u20131064. https:\/\/doi.org\/10.1097\/IAE.0000000000001313","journal-title":"Retina"},{"key":"7299_CR5","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/IAE.0000000000002164","volume":"39","author":"Y Onishi","year":"2019","unstructured":"Onishi Y, Yokoi T, Kasahara K et al (2019) Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia. Retina 39:1289\u20131298. https:\/\/doi.org\/10.1097\/IAE.0000000000002164","journal-title":"Retina"},{"key":"7299_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/IAE.0000000000004341","volume":"45","author":"Y Mizuno-Onishi","year":"2025","unstructured":"Mizuno-Onishi Y, Igarashi T, Uramoto K et al (2025) Four-year outcomes after intravitreal aflibercept for macular neovascularization in patients with pathologic myopia. Retina 45:464\u2013471. https:\/\/doi.org\/10.1097\/IAE.0000000000004341","journal-title":"Retina"},{"key":"7299_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10384-025-01270-8","volume":"70","author":"H Koizumi","year":"2026","unstructured":"Koizumi H, Honda S, Yasukawa T et al (2026) Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial. Jpn J Ophthalmol 70:139\u2013149. https:\/\/doi.org\/10.1007\/s10384-025-01270-8","journal-title":"Jpn J Ophthalmol"},{"key":"7299_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10384-025-01240-0","volume":"69","author":"T Iida","year":"2025","unstructured":"Iida T, Gomi F, Yasukawa T et al (2025) Japanese clinical guidelines for neovascular age-related macular degeneration. Jpn J Ophthalmol 69:639\u2013660. https:\/\/doi.org\/10.1007\/s10384-025-01240-0","journal-title":"Jpn J Ophthalmol"},{"key":"7299_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/s0161-6420(01)01007-7","volume":"109","author":"T Yoshida","year":"2002","unstructured":"Yoshida T, Ohno-Matsui K, Ohtake Y et al (2002) Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 109:712\u2013719. https:\/\/doi.org\/10.1016\/s0161-6420(01)01007-7","journal-title":"Ophthalmology"},{"key":"7299_CR10","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1097\/IAE.0000000000003863","volume":"43","author":"S Xie","year":"2023","unstructured":"Xie S, Lu H, Chen C et al (2023) Morphologic characteristics and progression patterns of macular neovascularization-related atrophy in eyes with pathologic myopia. Retina 43:1662\u20131672. https:\/\/doi.org\/10.1097\/IAE.0000000000003863","journal-title":"Retina"},{"key":"7299_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ajo.2015.11.014","volume":"162","author":"K Ohno-Matsui","year":"2016","unstructured":"Ohno-Matsui K, Jonas JB, Spaide RF (2016) Macular Bruch membrane holes in choroidal neovascularization-related myopic macular atrophy by swept-source optical coherence tomography. Am J Ophthalmol 162:133\u2013139e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.11.014","journal-title":"Am J Ophthalmol"},{"key":"7299_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.preteyeres.2018.10.005","volume":"69","author":"J Ruiz-Medrano","year":"2019","unstructured":"Ruiz-Medrano J, Montero JA, Flores-Moreno I et al (2019) Myopic maculopathy: current status and proposal for a new classification (ATN). Prog Retin Eye Res 69:80\u2013115. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.10.005","journal-title":"Prog Retin Eye Res"},{"key":"7299_CR13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","volume":"159","author":"K Ohno-Matsui","year":"2015","unstructured":"Ohno-Matsui K, Kawasaki R, Jonas JB et al (2015) International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol 159:877\u2013883. https:\/\/doi.org\/10.1016\/j.ajo.2015.01.022","journal-title":"Am J Ophthalmol"},{"key":"7299_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00417-011-1921-4","volume":"250","author":"R Uemoto","year":"2012","unstructured":"Uemoto R, Nakasato-Sonn H, Kawagoe T et al (2012) Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 250:989\u2013997. https:\/\/doi.org\/10.1007\/s00417-011-1921-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7299_CR15","doi-asserted-by":"publisher","first-page":"e0273613","DOI":"10.1371\/journal.pone.0273613","volume":"17","author":"KW Bae","year":"2022","unstructured":"Bae KW, Kim DI, Kim BH et al (2022) Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment. PLoS ONE 17:e0273613. https:\/\/doi.org\/10.1371\/journal.pone.0273613","journal-title":"PLoS ONE"},{"key":"7299_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00417-018-04214-w","volume":"257","author":"K Sayanagi","year":"2019","unstructured":"Sayanagi K, Uematsu S, Hara C et al (2019) Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 257:749\u2013757. https:\/\/doi.org\/10.1007\/s00417-018-04214-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7299_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/IAE.0000000000003930","volume":"44","author":"Y Kawashima","year":"2024","unstructured":"Kawashima Y, Hata M, Miyake M et al (2024) Macular chorioretinal atrophy and visual outcomes in ranibizumab- or aflibercept-treated myopic choroidal neovascularization. Retina 44:127\u2013135. https:\/\/doi.org\/10.1097\/IAE.0000000000003930","journal-title":"Retina"},{"key":"7299_CR18","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1167\/iovs.17-22633","volume":"58","author":"M Parravano","year":"2017","unstructured":"Parravano M, Scarinci F, Gilardi M et al (2017) Patchy chorioretinal atrophy changes at the posterior pole after ranibizumab for myopic choroidal neovascularization. Invest Ophthalmol Vis Sci 58:6358\u20136364. https:\/\/doi.org\/10.1167\/iovs.17-22633","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7299_CR19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ophtha.2017.12.005","volume":"125","author":"Y Fang","year":"2018","unstructured":"Fang Y, Yokoi T, Nagaoka N et al (2018) Progression of myopic maculopathy during 18-year follow-up. Ophthalmology 125:863\u2013877. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.005","journal-title":"Ophthalmology"},{"issue":"8","key":"7299_CR20","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1097\/IAE.0000000000001384","volume":"37","author":"JH Lee","year":"2017","unstructured":"Lee JH, Lee SC, Kim LS et al (2017) Choroidal thickness and chorioretinal atrophy in myopic choroidal neovascularization with anti-vascular endothelial growth factor therapy. Retina 37(8):1516\u20131522. https:\/\/doi.org\/10.1097\/IAE.0000000000001384","journal-title":"Retina"},{"key":"7299_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A et al (2016) Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology 123:617\u2013624. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.039","journal-title":"Ophthalmology"},{"key":"7299_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00417-020-04957-5","volume":"259","author":"M Pellegrini","year":"2021","unstructured":"Pellegrini M, Bernabei F, Mercanti A et al (2021) Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 259:911\u2013918. https:\/\/doi.org\/10.1007\/s00417-020-04957-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7299_CR23","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ophtha.2019.01.012","volume":"126","author":"Y Fang","year":"2019","unstructured":"Fang Y, Du R, Nagaoka N et al (2019) OCT-based diagnostic criteria for different stages of myopic maculopathy. Ophthalmology 126:1018\u20131032. https:\/\/doi.org\/10.1016\/j.ophtha.2019.01.012","journal-title":"Ophthalmology"},{"key":"7299_CR24","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1136\/bjophthalmol-2020-316866","volume":"105","author":"Z Li","year":"2021","unstructured":"Li Z, Wang W, Liu R et al (2021) Choroidal thickness predicts progression of myopic maculopathy in high myopes: a 2-year longitudinal study. Br J Ophthalmol 105:1744\u20131750. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316866","journal-title":"Br J Ophthalmol"},{"key":"7299_CR25","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1097\/IAE.0b013e3182509778","volume":"32","author":"AA Khanifar","year":"2012","unstructured":"Khanifar AA, Lederer D, Ghodasra JH et al (2012) Comparison of color fundus photographs and fundus autofluorescence images in measuring geographic atrophy area. Retina 32:1884\u20131891. https:\/\/doi.org\/10.1097\/IAE.0b013e3182509778","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07299-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07299-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07299-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:33:21Z","timestamp":1780893201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07299-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":25,"alternative-id":["7299"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07299-w","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of Osaka University Hospital approved the study, which adhered to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained in the form of an opt-out notice posted on the hospital\u2019s official website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}